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PRRT2 links infantile convulsions and
paroxysmal dyskinesia with migraine
ABSTRACT
Objective:Whole genome sequencing and the screening of 103 families recently led us to identify
PRRT2 (proline-rich-transmembrane protein) as the gene causing infantile convulsions (IC) with
paroxysmal kinesigenic dyskinesia (PKD) (PKD/IC syndrome, formerly ICCA). There is interfamilial
and intrafamilial variability and the patients may have IC or PKD. Association of IC with hemiplegic
migraine (HM) has also been reported. In order to explore the mutational and clinical spectra, we
analyzed 34 additional families with either typical PKD/IC or PKD/IC with migraine.
Methods:We performed Sanger sequencing of all PRRT2 coding exons and of exon-intron bound-
aries in the probands and in their relatives whenever appropriate.
Results: Two known and 2 novel PRRT2mutations were detected in 18 families. The p.R217Pfs*8
recurrent mutation was found inz50% of typical PKD/IC, and the unreported p.R145Gfs*31 in
one more typical family. PRRT2mutations were also found in PKD/IC with migraine: p.R217Pfs*8
cosegregated with PKD associated with HM in one family, and was also detected in one IC patient
having migraine with aura, in related PKD/IC familial patients having migraine without aura, and in
one sporadic migraineur with abnormal MRI. Previously reported p.R240X was found in one
patient with PKD with migraine without aura. The novel frameshift p.S248Afs*65 was identified
in a PKD/IC family member with IC and migraine with aura.
Conclusions: We extend the spectrum of PRRT2 mutations and phenotypes to HM and to other
types of migraine in the context of PKD/IC, and emphasize the phenotypic pleiotropy seen in
patients with PRRT2 mutations. Neurology 2012;79:2097–2103
GLOSSARY
HM 5 hemiplegic migraine; IC 5 infantile convulsion; PKD 5 paroxysmal kinesigenic dyskinesia; PNKD 5 paroxysmal
nonkinesigenic dyskinesia.
There is a long known relationship between human epilepsies and other paroxysmal brain dis-
orders, such as migraine, episodic ataxia, or paroxysmal dyskinesia—the occurrence of invol-
untary movements, whether spontaneous or triggered by various types of stimuli. Evidence for
shared pathophysiologic mechanisms underlying the concurrence of benign infantile convul-
sions (IC) and of paroxysmal kinesigenic dyskinesia (PKD) in the same patients or families was
obtained more than 15 years ago.1,2 This defined the autosomal dominant PKD/IC syndrome,3
formerly known as ICCA (infantile convulsions and paroxysmal choreoathetosis, MIM
602066).1 IC (or benign infantile seizures) are nonfebrile seizures with onset between 3 and
12 months of age and have a favorable outcome. Patients may develop PKD later in life. In
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PKD/IC families, individuals who inherited
the disease haplotypes had PKD, IC, or both.
Linkage of pure autosomal dominant IC at the
same genetic 16p12-q12 locus was obtained.4
Familial association of IC with hemiplegic
migraine (HM) has also been reported.5
Mutations in the PRRT2 gene were very
recently identified via exome or whole genome
sequencing in PKD6–8 and in PKD/IC and
IC patients and families.9,10 PRRT2 encodes a
proline-rich transmembrane protein of unknown
function. Interaction with synaptosomal-associ-
ated protein 25 (SNAP25)9 suggests a role in the
fusion of synaptic vesicles to the plasma mem-
brane. PRRT2 mutations identified so far in-
clude a recurrent and most frequent frameshift
mutation (c.649_650insC, p.R217Pfs*8) found
in most well-characterized PKD or IC families
and in less well-characterized patients or fami-
lies.6–10 Lack of mutant protein expression sug-
gested a loss-of-function mechanism.9
Altogether, the existence of interfamilial
and intrafamilial variability in the phenotypes
associated with PRRT2 mutations, and specif-
ically with the most frequent p.R217Pfs*8,
raised the question of the possible extension
of the mutational and phenotypic spectra. In
the present study, the phenotype spectrum
was extended to PKD with HM and PRRT2
mutations were also identified in PKD/IC fam-
ily members with more typical and frequent
forms of migraine, and in one sporadic patient
having complex migrainous disorder with MRI
abnormalities.
METHODS Patients and families. Patients and family
members reported in this study gave written informed consent
and were all collected according to appropriate ethical guidelines
and committees (CPPRB 09/40–n°AC-2008-438/n°DC-2009-
1002). A subset of the families have been previously reported.4,11
Inclusion criteria were the variable association of IC (afebrile seiz-
ures with onset at age 3–12 months without recognized etiology
and with a favorable outcome) with PKD later in life (attacks of
involuntary movements, usually of short duration, from seconds
to minutes, and precipitated by other sudden movements such as
standing up from a sitting position or being startled) (appendix e-1
on the Neurology® Web site at www.neurology.org). Patients with
pure PNKD (paroxysmal nonkinesigenic dyskinesia) or with pure
paroxysmal exercise-induced dyskinesia were not included. PKD/
IC families were classified as typical when no other neurologic
symptom was found in any of the patients. For those PKD/IC
families with various types of migraine (so-called atypical PKD/IC
families), the diagnosis and classification of migraine were performed
according to consensus guidelines according to the International
classification. Apart from the aforementioned symptoms, neurologic
workups were normal, including interictal EEGs that were performed
in a subset of the patients according to the international 10-20
system.
Sanger sequencing. DNA was extracted from whole blood
according to standard procedures. The coding exons and the
exon-intron boundaries of PRRT2 (Genbank NM_145239,
AK292393) were screened for mutations by Sanger sequencing
of genomic DNA. In family P2315 where PKD and HM cosegre-
gated (figure 1), the coding exons and the exon-intron boundaries of
the 3 known HM genes12 (ATP1A2: Genbank NM_000702; CAC-
NA1A: Genbank NM_000068, NM_023035, NM_001127221,
NM_001174080, NM_001127222; SCN1A: Genbank NM_
006920, NM_001165963, NM_001165964) were also screened.
Fifty-microliter PCR reactions were carried out with 80 ng of
genomic DNA and 10 pmol of each pair of forward and reverse
PRRT2 primers, using AccuPrime GC-Rich DNA Polymerase (Life
Technologies). Primer pairs are available upon request. All PCR
products were purified and both strands were sequenced at GATC
Biotech (http://www.gatc-biotech.com/) and the data were analyzed
with the Genalys 3.0 software.
Array comparative genomic hybridization experiment.
Array comparative genomic hybridization experiment was per-
formed on one patient (II-2) from the P2315 PKD/HM family,
using a 180K oligonucleotide microarray (SurePrint G3 Human
CGH Microarray Kit, 4 x 180K, Agilent Technologies, CA) as
previously described.13
Standard protocol approvals, registrations, and patient
consents. All experiments were conducted in accordance with the
Declaration of Helsinki and all procedures were carried out with the
adequate understanding and written consent of the subjects, and
after approval from the appropriate ethical committees (CPPRB
09/40–n°AC-2008-438/n°DC-2009-1002).
RESULTS AND DISCUSSION PRRT2 mutations in
typical PKD/IC. The recurrent frameshift and disease-
causing mutation (c.649_650insC, p.R217Pfs*8) was
found in 11 typical patients and families. A novel frame-
shift mutation (c.434delC, p.R145Gfs*31) was detected
in family P0114. In total, PRRT2mutations were found
in 12 of 24 (50%) patients or families with typical
PKD/IC syndrome (figure 1, table). This is fully con-
sistent with the formerly reported prevalence (52/103)
of PRRT2mutations in PKD/IC.9 PKD and IC showed
variable expression and some individuals were also unaf-
fected carriers. Mutations in noncoding sequences or
genomic rearrangements of the PRRT2 gene cannot
be excluded in the 12 remaining typical families. In
3 of them, missense variations (c.C413G, p.P138A;
c.G687A, p.R229K; c.C836T, p.P279S) were found
but did not segregate in other patients (data not shown).
Eight of these 12 were pure IC families, where genetic
heterogeneity has long been known.2
PRRT2 mutations in PKD/IC with various types of
migraine. The clinical spectrum of the recurrent
p.R217Pfs*8 PRRT2mutation was extended to the syn-
drome of PKD associated with HM in family P2315
(figure 2, figure 3, table). HM is a very rare subtype of
migraine that shows sporadic or autosomal dominant
2098 Neurology 79 November 20, 2012
ª 2012 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Figure 1 PRRT2 mutations in 12 families with typical PKD/IC
Females are represented by circles, males by squares. Left half-filled symbols are patients with paroxysmal kinesigenic dyskinesia (PKD). Right half-filled
symbols are patients with infantile convulsions (IC). Empty symbols are unaffected individuals. Family number is indicated at the top of each pedigree.
DNA from family members with no indication on the mutation status was not available. wt 5 wild-type. For convenience, names of frameshift mutations
have been simplified (R217fs is p.R217Pfs*8, R145fs is p.R145Gfs*31).
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inheritance. Mutations in 3 genes (ATP1A2, CAC-
NA1A, SCN1A) explain about 3/4 of familial patients
and a minority of sporadic patients.12 One ATP1A2
mutation has also been found in a family with IC
and HM.5 In the P2315 PKD/HM family having the
recurrent PRRT2mutation, neither a mutation in the 3
aforementioned HM genes nor a pathogenic genomic
alteration were detected by Sanger sequencing and by
array CGH, respectively (data not shown). The varia-
tion in phenotype between families with the same
PRRT2 mutation emphasizes the clinical and genetic
links between PKD, IC, and HM. How p.R217Pfs*8
causes the broad and variable phenotype of pure PKD,
pure IC, mixed PKD/IC, and mixed PKD/HM is thus
far unknown. The genetic defects reported so far in
PKD/IC and in HM, and in PNKD, may all lead to
altered synaptic functioning.9,14
The recurrent p.R217Pfs*8 mutation was detected
in another family (P4604) in 3 patients with PKD
and migraine without aura (figure 2). One more
patient in this family (II-3) who experienced migraine
without aura did not inherit the mutation; he did not
have PKD and might well be a phenocopy (overall
prevalence of migraine is 6% in males). p.R217Pfs*8
was also found in one patient (family P0111) who
had IC and migraine with visual aura and with tran-
sient speech difficulties. In addition, pR217Pfs*8 was
detected in one patient (PKD/IC family P0113) having
PKD and reporting migraine without aura. The previ-
ously reported p.R240X (c.C719T) nonsense mutation9
was also found in one family (P0115) member hav-
ing PKD and migraine without aura. A novel PRRT2
frameshift mutation (c.742delC, p.S248Afs*65) was
found in 3 patients (family P0116-12): one had IC
only, the other had PKD and GTCS, and the third had
IC and migraine with visual and aphasic aura. This and
the other novel p.R145Gfs*31 mutation mentioned
above were absent from current databases (1000 ge-
nomes database, NCBI SNP database) and from an
additional series of 95 (p.R145Gfs*31) and 200 (p.
S248Afs*65) control individuals of same ethnic origin.
The detection of PRRT2mutations in 6 PKD/IC-
related families with different forms of migraine includ-
ing the very rare hemiplegic type, the well-known links
between IC and HM, and the increased risk of
migraine in PNKD patients (Ptácek, unpublished
data) argue in favor of a nonspurious association of
typical migraine in the context of familial PKD/IC
with PRRT2 mutations. Indeed, the proportion of
migraineurs among PRRT2 mutation carriers (10/
37) was significantly increased as compared with the
overall migraine prevalence (z12%) (p5 0.02, 2-tailed
binomial test). This was even highly significant when
only the male carriers were considered (7/19 carriers vs
z6% in general population, p 5 0.00015, 2-tailed
binomial test). The link between PRRT2 and migraine
Table Summary of PRRT2 mutations detected in 18 patients and families with PKD/IC and related phenotypes
Pedigree Phenotypes Other features PRRT2 mutation Ethnic origin
P7-0101 PKD/IC Poland anomaly (patient II-2) p.R217Pfs*8 Canadian Caucasian
P1-0101 PKD/IC — p.R217Pfs*8 French Caucasian
P0111 PKD/IC/MWA — p.R217Pfs*8 French Caucasian
P0112 PKD/IC — p.R217Pfs*8 French Caucasian
P0113 PKD/IC/MWOA — p.R217Pfs*8 Malaysian Asiatic
P0114 IC — p.R145Gfs*31a French Caucasian
P0115a PKD/MWA — p.R240X French Caucasian
P0116-1 IC — p.R217Pfs*8 Argentinian Caucasian
P0116-12a PKD/IC/MWA GTCS (patient IV-1) pS248Afs*65a French Caucasian
P0116-15 PKD/IC — p.R217Pfs*8 French Caucasian
P011-12 PKD/IC — p.R217Pfs*8 Laotian Asiatic
P011-13 PKD/IC RE (patient III-1) p.R217Pfs*8 Argentinian Caucasian
P0131 PKD/IC — p.R217Pfs*8 Italian Caucasian
P4604a PKD/MWOA GTCS (patient III-1) p.R217Pfs*8 French Caucasian
P011-14 IC — p.R217Pfs*8 Argentinian Caucasian
P6-010 PKD/IC — p.R217Pfs*8 Malaysian Asiatic/Canadian Caucasian
P2315a PKD/HM — p.R217Pfs*8 French Caucasian
P011-23 PKD/IC — p.R217Pfs*8 Malaysian Asiatic
Abbreviations: GTCS5 generalized tonic-clonic seizure; HM5 hemiplegic migraine; IC5 infantile convulsion; MWA5migraine with aura; MWOA5migraine
without aura; PKD 5 paroxysmal kinesigenic dyskinesia; RE 5 rolandic epilepsy.
a The 6 pedigrees with various types of migraine and the 2 novel mutations reported in the present study.
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was also further strengthened by an independent study
where PRRT2 mutations are also found in several PKD
families with various types of migraine, including the rare
hemiplegic type (Gardiner et al., unpublished). That
PRRT2 might participate indifferent migraine types is
not surprising, given the previously reported overlaps
between HM, migraine with aura, and migraine without
aura,12,16 on the one hand, and the paroxysmal character-
istics shared by the other PRRT2-related brain dis-
orders on the other hand. To further evaluate the
Figure 2 PRRT2 mutations in 6 PKD/IC pedigrees with various types of migraine
Females are represented by circles, males by squares. Top left quarter-filled symbols are patients with paroxysmal kinesi-
genic dyskinesia (PKD). Top right quarter-filled symbols are patients with infantile convulsions (IC). Bottom left quarter-filled
symbols indicate patients with generalized tonic-clonic seizures. Bottom right quarter-filled gray symbols are patients with
various types of migraine: without aura (P0113, P0115, P4604), with visual aura (P0111, P0116-12), hemiplegic (P2315).
Empty symbols are unaffected individuals. Family number is indicated at the top of each pedigree. DNAs from family mem-
bers with no indication on the mutation status were not available. wt 5 wild-type. For convenience, names of frameshift
mutations have been simplified (R217fs is p.R217Pfs*8, S248fs is p.S248Afs*65).
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spectrum of PRRT2 mutations, we screened a cohort
of 49 patients with various types of migraine. The
recurrent and disease-causing p.R217fs*8 mutation
was detected in one woman (patient DL93) with
type I diabetes and having migraine that started at
age 48 years with complex sensitive aura (left hemi-
facial anesthesia), auditory aura (tinnitus), and swal-
lowing difficulties; she had MRI abnormalities
consisting of nodular hypersignals in the periventric-
ular white matter (data not shown). Of note, she had
no family history of PKD or IC.
In this study, the spectrum of PRRT2 mutations
was expanded to 2 novel mutations: p.R145Gfs*31
and p.S248Afs*65. Twelve other PRRT2 mutations,
including the 2 that were also found here (p.R217fs*8,
p.R240X), had been reported so far6–10 (figure 3).
The 2 novel mutations detected here are frameshift
and, in line with other PRRT2mutations including the
recurrent p.R217fs*8, are thus likely to cause loss of
function. The remarkable interfamilial and intrafamilial
pleiotropy seen in patients with various PRRT2 muta-
tions might depend on a complex interplay between a
given mutant allele, the genetic background of each
individual including genes with synaptic functions,
the neighboring genomic context,13 and the influence
of nongenetic factors. Our study also extends the
phenotypic spectrum of PRRT2 mutations to HM
and to other migraine subtypes in the context of
PKD/IC families. The recurrent PRRT2 mutation
was also detected in one sporadic migraineur with
abnormal MRI. A further search for PRRT2mutations
in pure HM and in much larger cohorts of patients
with more frequent types of migraine will be of great
interest. Overall our data add novel insights into the
multiple and somehow uncharacterized relationships
existing between various paroxysmal brain disorders.
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